GTx is a company of experienced individuals who are dedicated to developing novel targeted hormonal therapies to provide better medicines for patients. The Company focuses on the development of small molecules that selectively modulate the effects of certain hormones produced by the body. It is developing selective androgen receptor modulators, also referred to as SARMs, to potentially treat a number of serious diseases, including breast cancer, stress urinary incontinence and Duchenne muscular dystrophy.
To further explore treatments targeting diseases caused by abnormal androgen receptor signaling, GTx has a preclinical program to develop selective androgen receptor degraders (SARDs) for prostate cancer patients who no longer respond to androgen deprivation therapy.

Company Growth (employees)
Type
Public
HQ
Memphis, US
Founded
1997
Size (employees)
26 (est)-10%
Website
gtxinc.com
GTx was founded in 1997 and is headquartered in Memphis, US

Key People at GTx

Marc S. Hanover

Marc S. Hanover

President and Chief Operating Officer

GTx Office Locations

GTx has an office in Memphis
Memphis, US (HQ)
175 Toyota Plaza

GTx Data and Metrics

GTx Financial Metrics

USD

Net income (Q1, 2017)

(6.3 m)

EBIT (Q1, 2017)

(6.3 m)

Market capitalization (17-Aug-2017)

91 m

Cash (31-Dec-2016)

8.9 m
GTx's current market capitalization is $91 m.
USDFY, 2016

R&D expense

4.6 m

General and administrative expense

2.3 m

Operating expense total

6.9 m

EBIT

(6.9 m)

Net Income

(6.9 m)
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

3 m3.8 m4 m4.1 m4.6 m4.2 m

General and administrative expense

2 m2 m2.1 m2 m2.3 m2.1 m

Operating expense total

5 m5.9 m6.1 m6.1 m6.9 m6.3 m

EBIT

(5 m)(5.9 m)(6.1 m)(6.1 m)(6.9 m)(6.3 m)

Net Income

(48 m)34.9 m2.1 m(6.1 m)(6.9 m)(6.3 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

14.5 m17.9 m14.1 m8.9 m

Accounts Receivable

3.6 m

Inventories

442 k856 k2.6 m2.4 m

Current Assets

15.2 m50.2 m31.9 m24.3 m

PP&E

112 k29 k5 k81 k

Total Assets

15.6 m50.7 m32 m24.5 m

Accounts Payable

808 k512 k382 k1.2 m

Current Liabilities

4.6 m32.8 m30.2 m4.6 m

Additional Paid-in Capital

466 m512.5 m515.2 m551.1 m

Retained Earnings

(455.4 m)(494.8 m)(513.5 m)(531.2 m)

Total Equity

10.7 m17.8 m1.9 m19.9 m

Financial Leverage

1.5 x2.8 x17.2 x1.2 x
USDQ1, 2016

Cash

12.1 m

Current Assets

26.6 m

PP&E

12 k

Total Assets

26.7 m

Accounts Payable

903 k

Current Liabilities

3 m

Additional Paid-in Capital

534.9 m

Retained Earnings

(511.4 m)

Total Equity

23.7 m

Financial Leverage

1.1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(42.1 m)(39.4 m)(18.7 m)(17.7 m)

Depreciation and Amortization

384 k102 k43 k28 k

Accounts Payable

(899 k)(296 k)(130 k)838 k

Cash From Operating Activities

(44 m)(28.8 m)(20 m)(20.8 m)

Purchases of PP&E

(32 k)(5 k)(4 k)(90 k)

Cash From Investing Activities

9.2 m(31.2 m)16.2 m2.2 m

Cash From Financing Activities

1.2 m63.3 m63.3 m13.5 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(48 m)34.9 m2.1 m(6.1 m)(6.9 m)(6.3 m)

Depreciation and Amortization

4 k

Accounts Payable

992 k179 k438 k797 k184 k521 k1.4 m1.2 m514 k

Cash From Operating Activities

(4.8 m)

Purchases of PP&E

(8 k)

Cash From Investing Activities

3 m

Cash From Financing Activities

(210 k)

GTx Market Value History

Traffic Overview of GTx

GTx Company Life and Culture

You may also be interested in